Elicio Therapeutics (ELTX) Non-Current Assets (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Non-Current Assets came in at $6.5 million in Q1 2026, down 10.41% YoY from $7.2 million in Q1 2025, and down 0.95% on a QoQ basis from $6.6 million in Q4 2025.
Elicio Therapeutics (ELTX) Non-Current Assets (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Non-Current Assets data on file, last reported at $6.5 million in Q1 2026.
- Quarterly Non-Current Assets fell 10.41% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.8 million (down 15.04% YoY) and the FY2025 annual result came in at $6.6 million, down 12.48% from the prior year.
- Non-Current Assets declined to $6.5 million in Q1 2026, from $6.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $11.9 million in Q4 2022 to a low of $1.1 million in Q1 2023.
- A 5-year average of $7.6 million and a median of $7.2 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets sank 77.29% — and 2024, when it soared 807.89%.
- Tracing ELTX's Non-Current Assets over 5 years: stood at $11.9 million in 2022, then decreased by 9.62% to $10.8 million in 2023, then tumbled by 30.68% to $7.5 million in 2024, then decreased by 12.48% to $6.6 million in 2025, then dropped by 0.95% to $6.5 million in 2026.
- The last three Non-Current Assets figures came in at $6.5 million (Q1 2026), $6.6 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 5.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.85 Mn |
| Mar 31, 2026 | 6.49 Mn |
| Dec 31, 2025 | 6.55 Mn |
| Sep 30, 2025 | 6.82 Mn |
| Jun 30, 2025 | 6.93 Mn |
| Mar 31, 2025 | 7.24 Mn |
| Dec 31, 2024 | 7.49 Mn |
| Sep 30, 2024 | 7.74 Mn |
| Jun 30, 2024 | 9.06 Mn |
| Mar 31, 2024 | 10.35 Mn |
| Dec 31, 2023 | 10.80 Mn |
| Sep 30, 2023 | 11.06 Mn |
| Jun 30, 2023 | 11.39 Mn |
| Mar 31, 2023 | 1.14 Mn |
| Dec 31, 2022 | 11.95 Mn |
| Sep 30, 2022 | 4.64 Mn |
| Jun 30, 2022 | 4.93 Mn |
| Mar 31, 2022 | 5.02 Mn |
| Dec 31, 2021 | 5.27 Mn |
| Sep 30, 2021 | 5.55 Mn |